An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome.

Autor:	Drexel H; Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria.; Division of Angiology, Swiss Cardiovascular Center, University Hospital of Bern, Bern, Switzerland.; Private University of the Principality of Liechtenstein, Triesen, Liechtenstein.; Drexel University College of Medicine, Philadelphia, PA, USA., Coats AJS; University of Warwick, Coventry CV4 7AL, UK.; Monash University, Melbourne, Australia., Spoletini I; Department of Medical Sciences, Centre for Clinical and Basic Research, IRCCS San Raffaele Pisana, Via della Pisana, 235, 00163 Rome, Italy., Bilato C; Division of Cardiology, West Vicenza General Hospitals, Vicenza, Italy., Mollace V; Institute for Food Safety & Health University, 'Magna Graecia of Catanzaro', Catanzaro, Italy., Perrone Filardi P; Division of Cardiology, Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy., Rosano GMC; Department of Medical Sciences, Centre for Clinical and Basic Research, IRCCS San Raffaele Pisana, Via della Pisana, 235, 00163 Rome, Italy.
Jazyk:	angličtina
Zdroj:	European heart journal. Cardiovascular pharmacotherapy [Eur Heart J Cardiovasc Pharmacother] 2020 Apr 01; Vol. 6 (2), pp. 115-121.
DOI:	10.1093/ehjcvp/pvz079
Abstrakt:	Benefits and safety on statins have been well-established over 20 years of research. Despite this, the vast majority of patients are not adequately treated and do not achieve the low-density lipoprotein cholesterol target levels. This is mainly due to poor adherence, which is associated with dangerous and sometimes fatal outcomes. To increase adherence and prevent worse outcomes, a combination therapy with lower dosage of statins and new lipid-lowering drugs may be used. However, the implementation of new lipid-lowering drugs in European countries is still at the beginning. For these reasons, the aim of this position paper is to give an up-to-date indication from the ESC Working Group on Cardiovascular Pharmacotherapy in order to discuss the barriers towards statins adherence and new lipid-lowering drugs implementation in Europe. (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu